Vision Engineering Italy

Vision Engineering Italy s.r.l. (www.visioeng.com) is a SME settled in Rome, Italy. The mission of Vision Engineering Italy is to meet the medical needs through inventive and smart technological solutions.
The company focuses on the development of high-tech medical devices for the treatment of corneal diseases. The firm has created the new paradigm, VET-CXL, for treating ocular infections in veterinary medicine with unprecedent efficacy. Vet-cxl takes 15 minutes and is performed using our proprietary product portfolio, including a point-of-care UV-A device, VETUVIR, and a photo-active ophthalmic solution, EQUIRVIS. A multicenter randomized controlled clinical trial has determined that our innovative proprietary product is 84% superior to topical antimicrobials for treating infections.

Year of establishment:

2014

Number of employees:

0

Annual turnover:

Under 250.000 Euro

Reference year of turnover:

2018

Export turnover:

0

Activities:

MANUFACTURING OF TOOLS FOR RADIATION, ELECTRO-MEDICAL AND ELECTRO-THERAPEUTIC EQUIPMENT

Manufacturing of electro-medical equipment (including detached parts and accessories)

Manufacturing of medical-surgical and veterinary material

Trial research and development in the bio-technological field

Trial research and development in other natural sciences and engineering fields

VETERINARY SERVICES

No videos uploaded

No documents uploaded

Vetuvir is a point-of-care UV-A device for treating corneal infections in companion animals and horses. For veterinary practioners only. The device has shown - in multicenter controlled clinical trial, to be superior to topical antimicrobial therapy for the treatment of septic corneal ulcers in companion animals and horses. The device has been manufactured according to Dir. CEE 2001/95, 2006/42/CEE and 2014/30/UE.


Documents



Equirvis is a high-concentration riboflavin ophthalmic solution for exclusive use in vetrinary medicine. It has been specifically formulated for VET-CXL, allowing quick passage of the riboflavin into the corneal stroma for the most efficient treatment of septic corneal ulcers using VETUVIR.


Documents